<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684268</url>
  </required_header>
  <id_info>
    <org_study_id>NRSili</org_study_id>
    <nct_id>NCT00684268</nct_id>
  </id_info>
  <brief_title>Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders</brief_title>
  <acronym>NRSily</acronym>
  <official_title>Multicenter Study To Evaluate The Efficacy Of Silymarin In Addition To Combination-Therapy With Pegylated Interferon Alfa 2a (Peg-Ifn Alfa 2a) And Ribavirin In Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By chance the investigators found that iv. silibinin has a potent antiviral effect against
      the hepatitis C virus. Based on the results of the dose finding study (published) te optima
      dosing schedule is explored.This study will be evaluate whether the highest active dose given
      for the optimal time combined with standard of care will result in a sustained virologic
      response (=cure of hepatitis C).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since the publication of the first data the optimal dosing schedule is investigated
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>viral response at week 24</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sustained virologic response</measure>
    <time_frame>week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>week 72</time_frame>
    <description>start to end of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>on treatment nonresponders</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonresponders to previous antiviral combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silibinin</intervention_name>
    <description>comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days
sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion</description>
    <arm_group_label>Nonresponders to previous antiviral combination therapy</arm_group_label>
    <other_name>Silibinin infusions (20 mg/kg/d infused over 2 hours)given for 21 (either Monday -Friday or daily) or 28 days, continuation of antiviral combination therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silibinin</intervention_name>
    <description>20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued</description>
    <arm_group_label>on treatment nonresponders</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nonresponders to full dose PEG-IFN/RBV therapy

          -  Liver biopsy within the last 2 year

        Exclusion Criteria:

          -  Intolerance to one of the study drugs

          -  Coinfection with HIV/HBV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Wien</city>
        <zip>A1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol. 2011 Mar;54(3):591-2; author reply 592-3. doi: 10.1016/j.jhep.2010.09.009. Epub 2010 Oct 14.</citation>
    <PMID>21106270</PMID>
  </reference>
  <results_reference>
    <citation>Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008 Nov;135(5):1561-7. doi: 10.1053/j.gastro.2008.07.072. Epub 2008 Aug 3.</citation>
    <PMID>18771667</PMID>
  </results_reference>
  <results_reference>
    <citation>Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, Peck-Radosavljevic M, Ferenci P. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient. J Clin Virol. 2010 Oct;49(2):131-3. doi: 10.1016/j.jcv.2010.07.006. Epub 2010 Aug 14.</citation>
    <PMID>20709593</PMID>
  </results_reference>
  <results_reference>
    <citation>Rutter K, Scherzer TM, Beinhardt S, Kerschner H, Stättermayer AF, Hofer H, Popow-Kraupp T, Steindl-Munda P, Ferenci P. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antivir Ther. 2011;16(8):1327-33. doi: 10.3851/IMP1942.</citation>
    <PMID>22155914</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Peter Ferenci</investigator_full_name>
    <investigator_title>Prof. of Medicine</investigator_title>
  </responsible_party>
  <keyword>silibinin</keyword>
  <keyword>chronic hepatitis C</keyword>
  <keyword>peginterferon</keyword>
  <keyword>ribavirin</keyword>
  <keyword>nonresponders</keyword>
  <keyword>efficacy of iv. silibinin</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Silybin</mesh_term>
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

